Previous studies have revealed that over-expression of C12orf48 occurred in several cancer types, including myeloid leukemia cells [5], hepatocellular cancer [6], pancreatic cancer [7] and gastric cancer [8]. This evidence concerns the gene PARPBP and hepatocellular carcinoma.